Sign in

    Madhumita Yennawar

    Senior Equity Research Analyst at Leerink Partners

    Madhumita Yennawar, Ph.D., is a Senior Equity Research Analyst at Leerink Partners, specializing in diversified biopharmaceuticals with a particular focus on innovative clinical-stage companies. She covers specific companies such as Amylyx Pharmaceuticals and EOLS, routinely participating in their earnings calls and providing detailed research insights that influence sector investors. With a career rooted in scientific research and analytics, Yennawar joined Leerink Partners after earlier roles in industry and academic research; she brings rigorous data-driven analysis to her coverage. She holds a doctorate, maintains active professional securities credentials, and is recognized for her well-informed evaluations that contribute to investment decisions across the neurodegenerative and neurotoxin drug landscape.

    Madhumita Yennawar's questions to Mind Medicine (MindMed) (MNMD) leadership

    Madhumita Yennawar's questions to Mind Medicine (MindMed) (MNMD) leadership • Q4 2024

    Question

    Madhumita Yennawar of Leerink Partners inquired about the target patient population for MM120 in Generalized Anxiety Disorder (GAD), asking whether it would be for treatment-resistant patients or those with a specific severity level.

    Answer

    CEO Robert Barrow explained that while MindMed is pursuing a broad label for all GAD patients, payer dynamics might necessitate step therapy. Chief Medical Officer Dr. Dan Karlin added that market research and trial enrollment data show broad interest from patients with moderate to severe GAD, both treatment-experienced and naive, due to dissatisfaction with current options like SRIs. He anticipates high demand for a single-dose treatment with a favorable side-effect profile.

    Ask Fintool Equity Research AI

    Madhumita Yennawar's questions to Evolus (EOLS) leadership

    Madhumita Yennawar's questions to Evolus (EOLS) leadership • Q4 2024

    Question

    Madhumita Yennawar, on for Marc Goodman, asked for clarification on 2025 U.S. toxin market growth expectations and how Evolysse's in-vitro data on thermal and shear stress translates to clinical performance.

    Answer

    CFO Sandra Beaver clarified that while the market has historically been strong, the company's 2025 guidance prudently assumes a relatively flat filler market, offering potential upside. CMO Rui Avelar explained that the proprietary Cold-X technology better preserves HA's natural structure, leading to superior resistance to stress in lab tests. He stated this translated clinically to more correction and longer duration versus the control in studies, implying higher efficacy and longevity.

    Ask Fintool Equity Research AI

    Madhumita Yennawar's questions to Evolus (EOLS) leadership • Q3 2024

    Question

    Madhumita Yennawar, on behalf of Marc Goodman at Leerink Partners, asked for an overview of current trends in the overall toxin market and for anecdotes on the resonance of Evolus's marketing and promotional efforts during the quarter.

    Answer

    President and CEO David Moatazedi stated that the toxin market is showing expected Q3 seasonality but remains resilient and growing compared to other aesthetic procedures. He noted that promotional activities were a continuation of the first half's strategy and expressed confidence in a strong Q4, which is seasonally the strongest period.

    Ask Fintool Equity Research AI